Publicaciones en colaboración con investigadores/as de Harvard Medical School (70)

2024

  1. Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1

    EMBO molecular medicine, Vol. 16, Núm. 1, pp. 112-131

  2. The heterogeneous sensitivity of pediatric brain tumors to different oncolytic viruses is predicted by unique gene expression profiles

    Molecular Therapy Oncology, Vol. 32, Núm. 2

2023

  1. Cardiac Progenitor Cell Exosomal miR-935 Protects against Oxidative Stress

    Cells, Vol. 12, Núm. 18

  2. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways

    Cancer Discovery, Vol. 13, Núm. 11, pp. 2370-2393

  3. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  4. Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program

    Annals of Epidemiology, Vol. 77, pp. 1-12

  5. High-efficiency purification of divergent AAV serotypes using AAVX affinity chromatography

    Molecular Therapy - Methods and Clinical Development, Vol. 28, pp. 146-159

  6. Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening

    Nature Communications, Vol. 14, Núm. 1

  7. Long non-coding RNAs: definitions, functions, challenges and recommendations

    Nature Reviews Molecular Cell Biology, Vol. 24, Núm. 6, pp. 430-447

  8. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 7, pp. 1383-1392

  9. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

    Nature Medicine, Vol. 29, Núm. 3, pp. 632-645

  10. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory

    Cancer Cell, Vol. 41, Núm. 11, pp. 1911-1926.e8

  11. Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

    Blood cancer discovery, Vol. 4, Núm. 5, pp. 365-373

2022

  1. Ancestral library identifies conserved reprogrammable liver motif on AAV capsid

    Cell Reports Medicine, Vol. 3, Núm. 11

  2. Choice of vector and surgical approach enables efficient cochlear gene transfer in nonhuman primate

    Nature Communications, Vol. 13, Núm. 1

  3. Genetic and pharmacological inhibition of XBP1 protects against APAP hepatotoxicity through the activation of autophagy

    Cell death & disease, Vol. 13, Núm. 2, pp. 143

  4. Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcohol-associated hepatitis

    Hepatology, Vol. 75, Núm. 4, pp. 968-982

  5. Mutant IDH Inhibits IFNg–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma

    Cancer Discovery, Vol. 12, Núm. 3, pp. 812-835

  6. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

    Blood, Vol. 139, Núm. 6, pp. 835-844

  7. The deleterious effect of acetaminophen in cancer immunotherapy

    Annals of Oncology